The study at the Karolinska Institute in Stockholm, Sweden is designed to evaluate the safety and efficacy of Hemospan in patients suffering from chronic critical limb ischemia (CCLI), a debilitating condition that results from severely limited blood circulation to the legs. The primary endpoint is tissue oxygenation measured noninvasively.
Robert Winslow, chairman, president and CEO of Sangart, said: “The goal of this study is to demonstrate that Hemospan can increase oxygen supply to severely compromised tissue, conclusively establishing it as an oxygen-carrying plasma expander.”